EW vs SYK
Edwards Lifesciences and Stryker Corporation, both Healthcare
Stryker Corporation is the larger company at $118B against $50B. On trailing earnings SYK is the cheaper of the two at a P/E of 34.2 against 52.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +15% against -11% for SYK.
| Figure | EW | SYK |
|---|---|---|
| Last close | $90.77 | $330 |
| Market cap | $50B | $118B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 52.2 | 34.2 |
| 1-year return | +15% | -11% |
| 5-year return | -19% | +28% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 73% of the disclosed total.
Stryker Corporation
Revenue of $6.6B in Q2 2026, net income $1.3B. Its largest reported line is Instruments, 15% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.